Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Supreme Court
-
-
The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Since our prior article on the litigation between Amgen and Hospira over Hospira’s proposed biosimilar to Amgen’s Epogen®, there have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here, earlier this year the Supreme Court agreed to hear its first case arising under the Biosimilars Price...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The patent venue statue, 28 U.S.C. § 1400(b), states that “ny civil action for patent infringement may be brought in the judicial...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction The Amgen, Inc. and Amgen Manufacturing, Limited (“Amgen”) litigation against Hospira, Inc. (“Hospira”), filed in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Partner Nikki Gifford gave a presentation entitled “Intellectual Property – Recent Developments and Implications,” at the World...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Supreme Court heard oral arguments on Wednesday in its first biosimilar case. On a petition filed in Sandoz, Inc. v. Amgen, Inc., et...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported in this post, the Supreme Court granted certiorari in its first biosimilar case on Sandoz’s petition in Sandoz,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]